Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IC-17-7FB
- Development stage
- Preclinical
- Lead developer
- BioAsia Pharmaceutical
- Administration
- Oral
01
Overview
IC-17-7FB is a solid-state fermented fungal product derived from the fruiting body of *Isaria cicadae* Miquel (strain Ic-17-7), developed by BioAsia Pharmaceutical. Rich in active nucleosides such as adenosine and N6-(2-hydroxyethyl)adenosine (HEA), IC-17-7FB is being investigated in preclinical models for its potential therapeutic benefits in metabolic disorders. In a rat model of type 2 diabetes mellitus (T2DM), administration of IC-17-7FB significantly reduced fasting blood glucose levels and improved lipid profiles, including total cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C).
- Other names
- fruiting body of Isaria cicadae Miquel from strain Ic-17-7solid-state fermented Isaria cicadae fruiting body, strain Ic-17-7
Beyond the preview
Go deeper on IC-17-7FB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IC-17-7FB.